PACIFIC
2017
Durvalumab Consolidation after Chemoradiotherapy in Stage III NSCLC
In 713 patients with unresectable stage III NSCLC and no progression after concurrent chemoradiation, durvalumab consolidation for one year improved progression-free and overall survival compared with placebo.
Result
Efficacy: PFS and OS (co-primary)HR 0.52
Below 1 favours durvalumab consolidation for one year, above 1 favours placebo.
Event rates Durvalumab consolidation for one year 16.8 vs placebo 5.6 months
Also reported: 5-yr OS 42.9% vs 33.4%; 5-yr PFS 33.1% vs 19.0%.
- Subtopic
- Stage III NSCLC
- Design
- Double-blind RCT, 2:1 randomisation
- Relevance
- Important: one of several pillars.
- Source
- Antonia SJ, et al. N Engl J Med. 2017;377(20):1919-1929; Spigel DR, et al. J Clin Oncol. 2022;40(12):1301-1311.doi 10.1056/NEJMoa1709937
Discussion & critique
Established the 'PACIFIC regimen' as global standard for unresectable stage III NSCLC. Excluded EGFR-mutated disease; separate evidence applies there.